Neuro-oncology

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.

Neuro-oncology

Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, Prados MD, Haas-Kogan DA

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.

Neuro-oncology

Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, Prados MD, Haas-Kogan DA

Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM.

Neuro-oncology

Srinivasan R, Phillips JJ, Vandenberg SR, Polley MY, Bourne G, Au A, Pirzkall A, Cha S, Chang SM, Nelson SJ

Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM.

Neuro-oncology

Srinivasan R, Phillips JJ, Vandenberg SR, Polley MY, Bourne G, Au A, Pirzkall A, Cha S, Chang SM, Nelson SJ

MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.

Neuro-oncology

Chahal M, Xu Y, Lesniak D, Graham K, Famulski K, Christensen JG, Aghi M, Jacques A, Murray D, Sabri S, Abdulkarim B

MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.

Neuro-oncology

Chahal M, Xu Y, Lesniak D, Graham K, Famulski K, Christensen JG, Aghi M, Jacques A, Murray D, Sabri S, Abdulkarim B

TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.

Neuro-oncology

Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT

TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.

Neuro-oncology

Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT

Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific.

Neuro-oncology

Jun P, Hong C, Lal A, Wong JM, McDermott MW, Bollen AW, Plass C, Held WA, Smiraglia DJ, Costello JF

Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific.

Neuro-oncology

Jun P, Hong C, Lal A, Wong JM, McDermott MW, Bollen AW, Plass C, Held WA, Smiraglia DJ, Costello JF

Pages